Inhibition of platelet activity in vivo by amlodipine alone and combined with aspirin

International Journal of Cardiology

Volumn 62, Issue SUPPL. 2, 1997, Pages

  Folts, John D ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Dihydropyridine calcium channel blocker; Platelet inhibition

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; AMLODIPINE; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE;

ACUTE HEART INFARCTION; ANIMAL MODEL; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; EXPERIMENTAL MODEL; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS PREVENTION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0031593041     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(97)00248-9     Document Type: Conference Paper

References (42)

1. Hjemdahl-Monsen C.E., Lewis H.D., Cairns J., Chesebro J.H., Fuster V. Role of antithrombotic therapy in unstable angina, myocardial infarction and sudden death. J Am Coll Cardiol. 8:1986;67B-75B.
2. Ross R., Glomset J.A. The pathogenesis of atherosclerosis. N Engl J Med. 314:1986;488-500.
3. Kerson L.A., Olmos-Lau N. Review of ischemic cerebrovascular disease: Pathophysiology, clinical symptomatology, and their implications for therapy. Cardiovasc Rev Rep. 5:1984;227-239.
4. Cairns J.A., Gent M., Singer J. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med. 313:1985;1369-1375.
5. Lewis H.D., David J.W., Archibald D.G. Protective effects of aspirin against acute myocardial infarction and death in man with unstable angina. Results of a Veterans Administration cooperative study. N Engl J Med. 309:1983;396-403.
6. The Steering Committee of the Physicians' Health Study Research Group Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med. 321:1989;129-135.
7. Rao G.H.R., Johnson G.J., White J.G. Influences of epinephrine on the aggregation response of aspirin treated platelets. Prost Med. 5:1980;45-58.
8. Rao G.H.R., Escolar G., White J.G. Epinephrine reverses inhibitory influence of aspirin on platelet-vessel wall interactions. Thromb Res. 44:1986;65-74.
9. +2 uptake in human blood platelets. Am J Physiol. 239:1980;H483-H438.
10. Rao G.H.R., Reddy K.R., White J.G. Modification of human platelet response to sodium arachidonate by membrane modulation. Prostagland Med. 6:1981;75-90.
11. Rao G.H.R., Reddy K.R., White J.G. Low dose aspirin, platelet function and prostaglandin synthesis: influence of epinephrine and alpha adrenergic blockade. Prostagland Med. 6:1981;485-494.
12. Zucker M.L., Budd S.E., Dollar L.E., Chernoff S.B., Altman R. Effect of diltiazem and low-dose aspirin on platelet aggregation and ATP release induced by paired agonists. Thromb Haemost. 70:1993;332-335.
13. Pales J., Palacios-Araus L., Lopez A., Gaul A. Effects of dihydropyridines and inorganic calcium blockers on aggregation and on intracellular free calcium in platelets. Biochim Biophys Acta. 1064:1991;169-174.
14. Wallen N.H., Held C., Rehnqvist N., Hjemdahl P. Platelet aggregability in vivo is attenuated by verapamil but not by metoprolol in patients with stable angina pectoris. Am J Cardiol. 75:1995;1-6.
15. Folts J.D. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation. 83(Suppl IV):1991;IV3-IV14.
16. Bush L.R., Shebuski R.J. In vivo models of arterial thrombosis and thrombolysis. FASEB J. 4:1990;3087-3098.
17. Folts J.D., Rowe G.G. Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries. Thromb Res. 50:1988;5107-5116.
18. Folts J.D. Drugs for the prevention of coronary thrombosis: from an animal model to clinical trials. Cardiovasc Drugs Ther. 9:1995;31-43.
19. Bertha B.G., Folts J.D. Subendocardial and subepicardial segmental function changes in the dog heart due to gradual coronary flow reduction by an acutely developing thrombus. Cardiovasc Res. 8:1985;495-506.
20. Murdoch D., Heel R.C. Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs. 41:1991;478-505.
21. Burges R.A., Dodd M.G., Gardiner D.G. Pharmacologic profile of amlodipine. Am J Cardiol. 64:1989;10I-20I.
22. Dodd M.G., Gardiner D.G., Carter A.J., Sutton M.R., Burges R.A. The haemodynamic properties of amlodipine in anaesthetised and conscious dogs: comparison with nitrendipine and influence of beta-adrenergic blockade. Cardiovasc Drugs Ther. 3:1989;545-555.
23. Stopher D.A., Beresford A.P., Macrae P.V., Humphrey M.J. The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol. 12(Suppl 7):1988;S55-S59.
24. Mason R.G., Read M.S. Platelet responses to six agglutinating agents: species similarities and differences. Exp Mol Pathol. 6:1967;370-375.
25. Ardlie N.G., McGuiness J.A., Garrett J.J. Effect on human platelets of catecholamines at levels achieved in the circulation. Atherosclerosis. 58:1985;251-259.
26. Folts J.D., Rowe G.G., Rao G.H.R. Problem with aspirin an antithrombotic agent in coronary artery disease. Lancet. 1:1988;937-938.
27. Ahn Y.S., Harrington W.J. Calcium-channel blockers in thrombotic diseases. Adv lntern Med. 32:1987;137-154.
28. Ring M.E., Corrigan J.J. Jr., Fenster P.E. Effects of oral diltiazem on platelet function: alone and in combination with "low dose" aspirin. Thromb Res. 44:1986;391-400.
29. Hernandez R., Carvajal A.R., Armas-de-Hernandez M.J.et al. Amlodipine in hypertension: its effects on platelet aggregation and dynamic exercise. J Cardiovasc Pharmacol. 17(Suppl 1):1991;S25-S27.
30. Chou T.C., Lee K., Ding Y. Effect of felodipine-ER on blood pressure, platelet function, and rheological properties in hypertension. Can J Cardiol. 9:1993;423-427.
31. Sinzinger H., Virgolini I., Rauscha F., Fitscha P., O'Grady J. Isradipine improves platelet function in hypertensive patients. Eur J Clin Pharmacol. 42:1992;43-46.
32. 2 and serotonin as mediators of coronary artery vasoconstriction in vivo. J Am Coll Cardiol. 15:1990;718-726.
33. Beaughard M., Brasset M., John G., Massingham R. Failure of calcium channel blockade to reduce platelet-mediated cyclic flow variations in dogs with coronary stenosis and endothelial injury. J Cardiovasc Pharmacol. 26:1995;577-583.
34. Bonebrake F., Bertha B., Folts J.D. Calcium channel blockers do not inhibit acute platelet thrombus formation in stenosed canine coronary arteries. Clin Pharmacol Ther. 41(Abstract):1987;184.
35. Bonebrake F.C., Bertha B., Folts J.D., Rao G.H. Verapamil combined with aspirin for inhibiting epinephrine-stimulated platelet thrombus formation in stenosed canine coronary arteries. Coron Art Dis. 2:1991;487-492.
36. +2 handling in arterial thrombosis. Thromb Haemost. 57:1987;1-10.
37. Ahn Y.S., Jy W., Harrington W.J., Shanbaky N., Fernandez L.F., Haynes D.H. Increased platelet calcium in thrombosis and related disorders and its correction by nifedipine. Thromb Res. 45:1987;135-143.
38. Henry P.D., Bentley K. Suppression of atherosclerosis in cholesterol-fed rabbits treated with nifedipine. J Clin Invest. 68:1981;1366-1369.
39. Nayler, WG, Dillon, JS, Panagiotopoulos, S, Sturrock, WJ. Dihydropyridines and the ischaemic myocardium. In: Lichtlen, PR, editor. 6th Adalat Symposium. New therapy of ischemic heart disease and hypertension. Amsterdam: Excerpta Medica, 1986;486-497.
40. Henry P.D. Calcium antagonists as antiatherogenic agents. Ann NY Acad Sci. 522:1988;411-419.
41. Held P.H., Yusuf S., Furberg C.D. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Br Med J. 299:1989;1187-1192.
42. Lichtlen P.R., Hugenholtz P.G., Rafflenbeul W., Hecker H., Jost S., Deckers J.W. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet. 335:1990;1109-1113.